AzTrials
AzTrials

PeriodontitisNCT05680441

GCF Annexin-A1, Carbonic Anhydrase-1, and Elongation Factor-1 Gamma Levels in Periodontitis

An observational study of Periodontitis and Periodontal Inflammation, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study aimed to investigate gingival crevicular fluid (GCF) levels of possible novel biomarkers Annexin-A1 (ANX A1), Carbonic anhydrase- 1 (CA I), and Elongation Factor-1 Gamma (EF1-Ɣ) in health along with different periodontal diseases. Read more about this study

Who is it for?
Ages 20 to 61 yearsHealthy volunteers can take part
Conditions the study is for
Periodontitis, Periodontal Inflammation
What is being tested?
Peirodontal clinical measurements and gingival crevicular fluid sampling
Type of treatment
Pill or oral medicine
How many people
80 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Sep 2022to 16 Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 61 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: A total of 80 systemically healthy and non-smoker individuals(39 males, 41 females) aged 20-61 years were consecutively included.

Who may be able to join

  • Non-smokers with no history of smoking(determined by self-reporting)
  • Individuals who had at least 20 teeth(exclude wisdom teeth)

Who cannot join

  • Pregnant and lacting women
  • Patients who under any medication including immunosuppressants, steroids, non-steroidal anti-inflammatory drugs, antibiotics, antiepileptic drugs, calcium channel blockers, beta,blockers, anticoagulants, hormonal contraceptives and nutritional supplements within 6 monthsi topical antiseptic solutions in the last 3 months.
  • Patients with diagnosed medical illness such as diabetes mellitus, rheumatoid arthritis, cardiovascular diseases, immunological diseases.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Dokuz Eylul University, Faculty of Dentistry, Department of Periodontology

    Izmir, 35340

Other trials in Turkey (Türkiye)

About this study

Official title: Evaluation of Annexin-A1, Carbonic Anhydrase-1, and Elongation Factor-1 Gamma Levels in Periodontal Diseases

The study aimed to investigate gingival crevicular fluid (GCF) levels of possible novel biomarkers Annexin-A1 (ANX A1), Carbonic anhydrase- 1 (CA I), and Elongation Factor-1 Gamma (EF1-Ɣ) in health along with different periodontal diseases.

In total, 80 systemically healthy individuals were included in this study; 20 with periodontitis stage 3 grade B , 20 with periodontitis stage 3 grade C (P-Stage III/C), 19 with gingivitis, and 21 with clinically healthy periodontium. Probing depth, clinical attachment level, plaque index, and papillary bleeding index were recorded. GCF ANX A1, CA I and EF1-Ɣ levels were analyzed by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristics curve was used for estimating the under the curve.

Read the detailed description

Diagnosis of periodontal diseases and conditions was arranged according to the radiographic and clinical diagnostic criteria proposed by the 2017 World Workshop on Classifcation of Periodontal and Peri-implant Diseases and Conditions; 20 patients with Stage III Grade B generalized periodontitis , 20 patients with Stage III Grade C generalized periodontitis , 19 gingivitis patients and periodontally healthy volunteers were included in this study.

The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants. The measurements were performed using a Williams periodontal probe (Hu-Friedy, Chicago, IL, USA). All measurements were performed full mouth and at 4 sites (mesio-buccal, mid-buccal, distobuccal, and mid-lingual) for each tooth. Before clinical measurements, intra-examiner calibration was performed by measuring PPD and CAL values twice on five patients with one day interval resulting in intraclass correlation coefficients were 0.92 for PD and 0.90 for CAL.

GCF samples were taken from the buccal aspects of two nonadjacent interproximal sites in single-rooted teeth. In periodontitis groups, GCF was sampled from two deepest pockets of single-rooted teeth. Samples were collected from the sites with visible signs of inflammation in gingivitis group and without BOP in the healthy group. The selected areas were carefully cleared of supragingival plaque using sterile curettes, isolated with cotton rolls, and slightly air-dried to avoid contamination.

Standardized filter paper strips (PerioPaper, Proflow, Amityville, NY) were used for GCF sampling. Sterile paper strips were gently inserted into the gingival sulcus or pocket until mild resistance was felt and left there for 30 seconds. Mechanical irritation was avoided and strips visually contaminated with blood were discarded. A precalibrated electronic device measured the absorbed fluid volume (Periotron 8010, Oraflow, Amityville, NY). The readings were converted to an actual volume (microliter, μL) by reference to the standard curve. The paper strips were individually placed into a sterile polypropylene tube and stored at -80◦C for further analysis.

Annexin-A1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3158). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the Annexin-A1 kit were 0.20-20 ng/mL, sensitivity 0.2 ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.

Carbonic anhydrase 1 levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: SRB-T-88927). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the CA I kit were 3.12-200ng/mL, sensitivity <1.875ng/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.

EEF1G levels were studied with commercially available kits using the ELISA method (Bioscience SRB, catalog no: 201-12-3732). The optical density was measured spectrophotometrically at a wavelength of 450 nm (Tecan). The assay ranges for the EF1- Ɣ kit were 31.25-2000pg/mL, sensitivity <12.4pg/mL, and the intra- and interassay coefficients of variance (CV%) were<10%. The results were presented as ng.

Statistical analysis was performed using non-parametrical techniques. Comparisons between the study groups were performed using the Kruskal-Wallis test. When there were significant differences (p < 0.05), post-hoc 2-group comparisons were assessed with Bonferroni-corrected Mann-Whitney U tests, and p-values < 0.05 was considered significant. All data analysis was performed using a statistical package (Abacus Concepts Inc., Berkeley, CA, USA). The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), receiver operating characteristic (ROC) curve, and area under the ROC curve (AUC) of the test dataset were assessed. P values < 0.05 were considered statistically significant, and 95% confidence intervals (CIs) were calculated.

Being tested
Peirodontal clinical measurements and gingival crevicular fluid sampling
Medical subject headings
Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Peirodontal clinical measurements and gingival crevicular fluid samplingOther

    The clinical periodontal examination of the healthy and periodontitis subjects consisted of plaque index (PI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP) recorded. CAL was calculated by adding GR to the PPD values. Averages for full mouth PPD, CAL, and the percentage of sites with BOP were calculated for each subject. A single calibrated examiner (VO) conducted a full mouth periodontal examination of all participants.

Study groups in NCT05680441
Study groupRoleWhat they receive
Healty groupThe controls/Healthy group were the individuals with well-maintained oral hygiene without no periodontal disease history or symptoms with a probing pocket depth (PPD) of ≤3 mm and bleeding on probing (BOP) of (+) ≤10.
Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling
Periodontitis stage 3 grade BStage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis. These patients were graded according to the bone loss%/age index (Grade B, 0.25-1.00).
Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling
Periodontitis stage 3 grade CStage III periodontitis patients had at least 4 interdental sites clinical attachment level (CAL)> 5 mm due to periodontitis, radiographic bone loss reaching to the mid-third of the root or beyond, teeth loss less than 4 teeth due to periodontitis.Since the bone loss (%)/age values were >1.0, all periodontitis patients were considered grade C.
Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling
GingivitisOnly generalized gingivitis patients were included in this study. Individuals presenting with a BOP≥30% and PPD≤3 mm without radiographic bone loss and attachment loss were considered to have gingivitis.
Receives: Other: Peirodontal clinical measurements and gingival crevicular fluid sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gingival crevicular fluid Annexin-A1 levels

    ng

    Measured: 24 hours after clinical periodontal measurements

  2. Gingival crevicular fluid Carbonic Anhydrase-1 levels

    ng

    Measured: 24 hours after clinical periodontal measurements

  3. Gingival crevicular fluid Elongation Factor-1 Gamma- Ɣ levels

    ng

    Measured: 24 hours after clinical periodontal measurements

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jan 2023
  2. Study start1 Sep 2022
  3. Primary completion1 Dec 2022
  4. Study completion16 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05680441
Sponsor's protocol ID
CANSU35
Status last verified
Jan 2023
First submitted
26 Dec 2022
Last updated
12 Jan 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Periodontitis and Periodontal Inflammation, run by Dokuz Eylul University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gingival crevicular fluid Annexin-A1 levels (time frame: 24 hours after clinical periodontal measurements). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in